Teva ($TEVA) - Knocking on the door of investment grade
S&P upgrades Teva to BB+, putting the pharma giant one notch away from a massive institutional liquidity event.
Introduction
Shareholders received an early holiday gift on the morning of December 24th. Teva announced that S&P Global Ratings has upgraded its long-term issuer credit rating to BB+ from BB. Simultaneously, Moody’s revised its outlook to Positive.
On the surface, this is a standard credit update. But from a capital markets perspective, Teva has just entered the most critical phase of its corporate rehabilitation. They are now officially a “Rising Star” candidate.
The Data - Improving, but leverage still needs to come down
S&P’s move to BB+ places Teva at the very ceiling of the High Yield (junk) category. To understand why this happened, we have to look at the leverage ratios.
Current State: S&P notes adjusted leverage declined to 4.4x as of Q3 2025.
The Target: They expect this to fall below 4.25x in upcoming quarters.
Moody’s View: Moody’s is slightly more optimistic about the trajectory, projecting leverage to trend toward 3.5x within 12 to 18 months. This explains their “Positive” outlook, which implies a potential upgrade is on the horizon if targets are met.
The trend is clear, Teva is very diligently brining down debt and this will continue at least until it is down to 2x Net debt to EBITDA.
This is a validation of the “Pivot to Growth” strategy. Revenue growth in branded medicines is finally offsetting the erosion in the generics business, allowing for genuine organic deleveraging rather than just asset sales.
The institutional perspective
Why does the difference between BB+ (current) and BBB- (the next step up) matter?
It comes down to Investment Policy Statements.
The world of fixed income is bifurcated. A massive portion of global capital (pension funds, insurance float, sovereign wealth) operates under strict mandates that forbid the purchase of “Speculative Grade” securities. As long as Teva is rated BB+, it is uninvestable for these pools of capital. Here is an overview of current top holders of the shares:
Phoenix, Menora, Harel, Migdal, and Clal arę all Israeli institutional giants. They hold Teva shares both for their own accounts (investing insurance premiums) and on behalf of members in their pension and provident funds. They are domestic anchor investors who are required to hold significant exposure to the local index (TA-35), of which Teva is a major constituent. Blackrock and FMR (Fidelity) are massive asset managers. Lingotto is the most interesting on the list; it is an investment management company owned by Exor N.V. (the holding company of the Agnelli family, which controls Ferrari, Stellantis, etc.). This is effectively a massive Family Office. Rubric Capital Management is a US-based hedge fund who is often value/contrarian focused. PointState Capital is macro/equity hedge fund.
However, Teva is now in the “Crossover” zone.
Front-running the upgrade: Active managers who can hold high yield but benchmark against aggregate indices will often buy BB+ credits before they hit Investment Grade / IG. They want to capture the spread compression that happens when a bond graduates from “Junk” to “IG.”
The passive wave: If Teva secures that final notch up to BBB- (S&P) or Baa3 (Moody’s), it triggers forced buying from passive Investment Grade funds. This is a volume event that provides a floor for the bond price and, by proxy, reduces the cost of equity.
By moving to BB+, Teva has signaled to the market that the “default risk” premium is evaporating.
What we need in the meantime
While Moody’s moved its outlook to Positive, S&P kept its outlook at Stable. This is a noteworthy distinction. S&P is saying, Teva have improved enough to be BB+, but we do not see the company becoming Investment Grade (BBB-) in the immediate term.”S&P requires a longer track record of sub-4.25x leverage before they will open the gate to Investment grade status. The good news here is that Teva will show every quarter that they are on track to achieve this.
The projected deleveraging relies on the continued success of the branded portfolio. Pharma is a volatile sector. A single clinical trial failure or a new patent challenge on a key asset could halt the revenue growth required to bring that denominator (EBITDA) up. The debt (the numerator) is still massive in absolute terms.
Conclusion
Teva has moved from a “distressed” story to a “deleveraging” story. For shareholders, the upgrade to BB+ is a signal that the risk of bankruptcy is effectively off the table for the near future.
However, the Investment Grade party isn’t starting yet. We are in the waiting room. Many will be watching the next two quarters of EBITDA specifically to see if that 3.5x leverage target from Moody’s is mathematically realistic or just corporate optimism.
I have a position in Teva, the above is as always not investment advice.
With that, thanks for reading I truly appreciate the interest. Below are a few ideas for further readings and inspirations.